Ischemic stroke
Coffee may pull the trigger
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Stroke is a leading cause of severe, long-term disability and the third leading cause of death in the United States, affecting more than 700,000 people yearly.1 Clinic- and population-based studies have documented the role of traditional and novel risk factors.1,–,3 Most are traits, chronic conditions, or behaviors that affect the risk of stroke following many years of exposure. Less is known about potential triggers of stroke in the period immediately preceding stroke onset, such as physical exercise, drug use, and intake of alcohol or coffee. Coffee is of particular interest because of its widespread use. Consumption in some countries exceeds 10 kilograms per person per year, which corresponds to more than 100 g of pure caffeine per year. Caffeine may well be the most widely consumed drug in the world,4 but coffee consumption is socially acceptable and is generally thought to be a safe habit.
In this issue of Neurology®, Mostofsky and colleagues5 challenge the idea of coffee being safe. They test the hypothesis that coffee intake is associated with a transient increase in risk of ischemic stroke. In a multicenter case-crossover study, they studied 390 subjects after an acute ischemic stroke event. Each subject's coffee consumption in the hour before stroke …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Articles
Coffee and acute ischemic stroke onsetThe Stroke Onset StudyE. Mostofsky, G. Schlaug, K.J. Mukamal et al.Neurology, September 29, 2010 -
Articles
Caffeine, postmenopausal estrogen, and risk of Parkinson’s diseaseA. Ascherio, H. Chen, M.A. Schwarzschild et al.Neurology, March 11, 2003 -
Article
Diabetes Mellitus, Glycemic Traits, and Cerebrovascular DiseaseA Mendelian Randomization StudyMarios K. Georgakis, Eric L. Harshfield, Rainer Malik et al.Neurology, January 25, 2021 -
Articles
The neuroprotective effects of caffeineA prospective population study (the Three City Study)K. Ritchie, I. Carrière, A. de Mendonça et al.Neurology, August 06, 2007